College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, USA.
J Vet Intern Med. 2021 Mar;35(2):1018-1030. doi: 10.1111/jvim.16098. Epub 2021 Mar 3.
Little is known regarding the comparative efficacy of various irradiation strategies used to treat intranasal carcinomas (INC) in cats.
Investigate outcomes and prognostic factors associated with survival for cats with INC.
Forty-two cats with INC that underwent radiotherapy (RT).
Single-arm retrospective study. Medical record review for cats with INC that underwent RT at 1 of 7 veterinary RT facilities. Irradiation protocols categorized as: definitive-intent fractionated RT (FRT), definitive-intent stereotactic RT (SRT), and palliative-intent RT (PRT). Median overall survival time (OST) and disease progression-free survival (PFS; documented by advanced transverse imaging, or recurrence of symptoms) were calculated. Associations between tumor stage, RT protocol/intent, and adjunctive treatment usage and outcome were calculated.
Cats underwent SRT (N = 18), FRT (N = 8), and PRT (N = 16). In multivariate modeling, cats received definitive-intent treatment (DRT; FRT/SRT) had significantly longer median PFS (504 days, [95% confidence interval (CI): 428-580 days] vs PRT 198 days [95% CI: 62-334 days]; p = 0.006) and median OST [721 days (95% CI: 527-915 days) vs 284 days (95% CI: 0-570 days); p = 0.001]). Cats that underwent second DRT course at time of recurrence lived significantly longer than cats that received 1 RT course (either DRT or PRT [median OST 824 days (95% CI: 237-1410 days) vs 434 days (95% CI: 277-591 days); p = .028]).
In cats with INC, DRT is associated with prolonged OST and PFS as compared to PRT. If tumor progression occurs, a second course of DRT should be considered.
对于治疗猫鼻腔内肿瘤(INC)的各种放射治疗策略的比较疗效,人们知之甚少。
研究与接受放射治疗的 INC 猫的生存相关的结果和预后因素。
42 只接受放疗(RT)的 INC 猫。
单臂回顾性研究。对在 7 家兽医放射治疗中心中的 1 家接受 RT 的 INC 猫的病历进行回顾。将照射方案分为:根治性分次 RT(FRT)、根治性立体定向 RT(SRT)和姑息性 RT(PRT)。计算中位总生存时间(OST)和疾病无进展生存(PFS;通过高级横断成像记录,或症状复发)。计算肿瘤分期、RT 方案/意图以及辅助治疗的使用与结果之间的相关性。
猫接受 SRT(N = 18)、FRT(N = 8)和 PRT(N = 16)。在多变量建模中,接受根治性治疗(FRT/SRT)的猫的中位 PFS 显著更长(504 天[95%置信区间(CI):428-580 天] vs PRT 198 天[95%CI:62-334 天];p=0.006),中位 OST 也更长[721 天(95%CI:527-915 天)vs 284 天(95%CI:0-570 天);p=0.001]。在复发时接受第二次 DRT 疗程的猫比仅接受 1 次 RT 疗程(无论是 DRT 还是 PRT)的猫存活时间显著更长(中位 OST 824 天[95%CI:237-1410 天] vs 434 天[95%CI:277-591 天];p=0.028])。
在 INC 猫中,与 PRT 相比,DRT 与 OST 和 PFS 的延长相关。如果肿瘤进展发生,应考虑第二次 DRT 疗程。